Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

Homocystinuria Clinical Trial

Official title:

A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058), Administered Subcutaneously in Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (COMPOSE)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03406611
• Other study ID #: CBS-HCY-CT-01
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: January 22, 2019
• Est. completion date: December 2026

Study information

• Verified date: January 2024
• Source: Travere Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Homocystinuria caused by Cystathionine Beta-Synthase (CBS) Deficiency is a rare autosomal-recessive metabolic condition characterized by an excess of homocysteine (Hcy) in the plasma, tissues and urine. It is due to reduced or absent activity of the CBS enzyme, and is also known as classical homocystinuria. The symptoms associated with homocystinuria are variable in severity and time of onset across patients. Some affected individuals may have mild signs of the disorder; others may have multi-systemic involvement including potentially life-threatening complications. Homocystinuria can affect many different organ systems of the body; the four most commonly involved are the eyes, central nervous system, skeleton, and the vascular system. The current approaches to treatment of homocystinuria patients include a highly restrictive diet and use of dietary supplements. Lifetime compliance with this diet is poor. Pegtibatinase (TVT-058) represents a novel therapeutic approach that incorporates the use of a modified version of the native, human CBS (hCBS) enzyme. The goal of treatment is to introduce the CBS enzyme into circulation, resulting in reduced Hcy levels, increased cystathionine (Cth) and cysteine (Cys) levels.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 32
• Est. completion date: December 2026
• Est. primary completion date: June 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 65 Years

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of homocystinuria based on genetic confirmation and plasma tHcy =50 micromoles and documentation of previous tHcy level =80 micromoles
• Willing and able to provide written, signed informed consent and to comply with all study related procedures.
• Subjects born biologically as female who are of child-bearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study. Subjects born biologically as male who identify as female and are not of childbearing potential are not required to undergo pregnancy tests
• Sexually active subjects who have childbearing potential or those who have partners of childbearing potential must be willing to use acceptable methods of contraception while on the study and for 4 weeks after the end of study
• Willing to maintain a stable diet with no significant modifications while on study and complete a daily diet diary.

Exclusion Criteria:

• Previous exposure to pegtibatinase and/or previous participation in a clinical trial that included administration of pegtibatinase
• Use of any investigational product or investigational medical device within 30 days prior to Screening, or while on study
• Use or planned use of any injectable drugs containing PEG (other than pegtibatinase or COVID-19 vaccines), including medroxyprogesterone (eg, Depo-Provera) injection, within 3 months prior to Screening and during study participation
• Known hypersensitivity to PEG-containing product or any components of pegtibatinase
• A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody
• A history of organ transplantation, chronic immunosuppressive therapy, or substance abuse
• Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study
• Concurrent disease or condition or planned major surgery that would interfere with study participation or safety in the opinion of the investigator.
• Any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study
• Major surgery planned during the study period

Related Conditions & MeSH terms

• Homocystinuria

Intervention

Drug:
• Pegtibatinase
Pegtibatinase sterile solution for subcutaneous injection
• Placebo
Normal saline for subcutaneous injection

Locations

Country	Name	City	State
United States	Travere Investigational Site	Aurora	Colorado
United States	Travere Investigational Site	Boston	Massachusetts
United States	Travere Investigational Site - Virtual Site	Culver City	California
United States	Travere Investigational Site	Indianapolis	Indiana
United States	Travere Investigational Site	Miami	Florida
United States	Travere Investigational Site	New York	New York
United States	Travere Investigational Site	Philadelphia	Pennsylvania
United States	Travere Investigational Site	Portland	Maine

Sponsors (1)

Lead Sponsor	Collaborator
Travere Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of AEs	Incidence of AEs (by type, severity and relationship to study drug)	Through double-blind study completion, approximately 10 months per patient
Primary	Anti-pegtibatinase antibodies	Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers	Through double-blind study completion, approximately 10 months per patient
Primary	Anti-PEG antibodies	Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers	Through double-blind study completion, approximately 10 months per patient
Secondary	Changes in pegtibatinase levels	Changes in pegtibatinase levels following single and repeat administration at specified timepoints	Through double-blind study completion, approximately 10 months per patient
Secondary	Changes in Met cycle metabolites levels - tHcy	Changes in total homocysteine levels in micromoles	Through double-blind study completion, approximately 10 months per patient
Secondary	Changes in Met cycle metabolites levels - total Cys	Changes in total cysteine levels in micromoles	Through double-blind study completion, approximately 10 months per patient
Secondary	Changes in Met cycle metabolites levels - Met	Changes in methionine levels in micromoles	Through double-blind study completion, approximately 10 months per patient
Secondary	Changes in Met cycle metabolites levels - Cth	Changes in cystathionine levels in micromoles	Through double-blind study completion, approximately 10 months per patient
Secondary	Changes in Met cycle metabolites levels - Phe	Changes in phenylalanine levels in micromoles	Through double-blind study completion, approximately 10 months per patient
Secondary	Descriptive ophthalmology examination findings	Comprehensive ophthalmological examination (for each eye: visual acuity [myopia, hyperopia, exotropia], slit lamp examination [ectopic lentis, cataracts, corneal abrasion, and uveitis], retinal examination [retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)]). Assessment of presence and severity of findings.	Through double-blind study completion, approximately 10 months per patient
Secondary	Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans		Through double-blind study completion, approximately 10 months per patient
Secondary	Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score		Through double-blind study completion, approximately 10 months per patient
Secondary	Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL]	The Quality of Life in Neurological Disorders [Neuro-QoL] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old	Through double-blind study completion, approximately 10 months per patient
Secondary	Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36]		Through double-blind study completion, approximately 10 months per patient
Secondary	Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D]		Through double-blind study completion, approximately 10 months per patient